Business Trends– category –
-
OS Therapies Strengthens FDA & MHRA Alignment, Joins Project Orbis for OST-HER2 Metastatic Osteosarcoma Program
OS Therapies USA Overview OS Therapies announced strengthened alignment with the FDA and MHRA and approval to join Project Orbis for its lead candidate, OST-HER2 (a next-generation tunable ADC) program for metastatic osteosarcoma. Projec... -
Nutshell Therapeutics’ NRF2 Molecular Glue Degrader NTS231 Clears FDA IND, Becomes China’s First and World’s Second to Enter Clinical Development
Insight, China's Pharmaceutical Industry China Overview Nutshell Therapeutics' NRF2 molecular glue degrader, NTS231, has cleared FDA IND, becoming the first from China and second globally to enter clinical development as a novel therapeu... -
Akeso’s EGFR/TROP2 Bispecific ADC AK158D1 Cleared for Phase I Clinical Trial in Advanced Solid Tumors by China’s NMPA
PR Newswire China Overview Akeso Inc., a Chinese biopharmaceutical company, announced that its EGFR and TROP2 bispecific antibody-drug conjugate (ADC) candidate, AK158D1, has received clearance from China's National Medical Products Admi...
